Program for the Introduction Into Clinical Practice of the Principles of Personalized and Preventive Medicine Based on the Isolation of Gene Polymorphism in Schizophrenia in People of the Kazakh Ethnic Group

March 13, 2023 updated by: Ildar Fakhradiyev, Asfendiyarov Kazakh National Medical University

Preventive and Personalized Medicine (2021-2023)

This is a GWAS study that aims to identify possible candidate genes associate to schizophrenia by exploring single nucleotide polymorphism (SNP) in a group of schizophrenia, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associated with schizophrenia

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.

Study Type

Observational

Enrollment (Actual)

700

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Kazakhstan
      • Almaty, Kazakhstan, 050000
        • Republican Scientific and Practical Center for Mental Health

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Kazakh population

Description

Inclusion Criteria:

  • persons of Kazakh nationality having this ethnicity in the 3rd generation
  • age from 18 to 65 years old;
  • the dispensary in a psychiatric institution at the place of residence with a diagnosis of "Paranoid schizophrenia";
  • the duration of the disease is at least 1 year (from the moment of taking under dispensary supervision):
  • absence of severe and chronic somatic diseases;
  • absence of severe and chronic neurological diseases;
  • absence of comorbid drug addiction pathology;
  • signed informed consent to conduct this study

Exclusion Criteria:

  • persons of non-Kazakh nationality and Kazakh nationality, not confirmed until the 3rd generation
  • age less than 18 years old and over 65 years old;
  • those who are on dispensary registration in a psychiatric institution at the place of residence with a diagnosis not related to ICD-10 under the heading F20.0 "Paranoid schizophrenia";
  • having a disease duration of less than 1 year (from the moment of taking under dispensary supervision):
  • having severe and chronic somatic diseases;
  • having severe and chronic neurological diseases;
  • having comorbid narcological pathology;
  • not signed informed consent to conduct this study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Experimental group:
Patients with schizophrenia
Genetic: DNA analysis
GWAS
Control group
Patients without schizophrenia
Genetic: DNA analysis
GWAS

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
number of SNPs associated with schizophrenia
Time Frame: 1 year
Using GWAS to identify candidate genes associate with schizophrenia
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Asfendiyarov Kazakh National Medical University

Investigators

  • Principal Investigator: Kuanysh Altynbekov, PhD, Republican Scientific and Practical Center for Mental Health

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 30, 2022

Primary Completion (Actual)

January 20, 2023

Study Completion (Actual)

January 20, 2023

Study Registration Dates

First Submitted

September 25, 2021

First Submitted That Met QC Criteria

October 21, 2021

First Posted (Actual)

October 25, 2021

Study Record Updates

Last Update Posted (Actual)

March 14, 2023

Last Update Submitted That Met QC Criteria

March 13, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1203 (Other Grant/Funding Number: VA Catalyst)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Schizophrenia

Clinical Trials on DNA analysis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe